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ABSTRACT
Objectives: The tests conducted were intended to analyze the concentration of p53 protein and anti-p53 autoantibodies 
in serum of women with ovarian tumours. 
Material and methods: The study included patients with diagnosed ovarian cancer: Cystadenoma serosum or Cystadeno-
carcinoma papillare serosum at IIIc stage (including 10 women who had G1, 14 women who had G2 and 30 women who 
had G3 staging). Concentrations of parameters were measured by ELISA. 
Results: The analysis of the obtained results showed statistical significance between the concentration of p53 protein de-
pending on the degree of differentiation of G1 and G3 (p < 0.001) and anti-p53 autoantibodies depending on the degree 
of differentiation of G1 and G2 (p < 0.05) as well as G2 and G3 (p < 0.01). In addition, the determined p53/anti-p53 autoan-
tibodies ratio was only significant between G1 and G2 (p < 0.05), as was the assessment of the percentage of the tested 
parameters in the immune complex.
Conclusions: Immune system disorders involving the p53 protein and anti-p53 autoantibodies may be one of the  immune 
mechanisms involved in the pathogenesis of ovarian serous cancer.
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INTRODUCTION 
In the course of ovarian carcinoma, an important role 
plays the immune response directed against neoplastic cells, 
especially apoptosis. It is one of the key processes leading 
to initiation of carcinogenesis [1].
In the regulation of apoptosis, a significant role is also 
performed by protein p53, which participates in the intrinsic 
pathway of the process, called a p53-dependent mitochon-
drial pathway. Protein p53, encoded by the gene TP53 and 
localized on chromosome 17p13.1, is crucial for a proper 
course of the cell cycle and therefore, is called a guardian of 
the genome. One of the major functions of the p53 protein is 
to activate transcriptions of genes responsible for initiating 
apoptosis in response to DNA damage, which may be linked 
to its anti-tumour activity [2, 3]. The loss of protein p53 activ-
ity was shown in the pathogenesis of many neoplasms, while 
the most often mechanism leading to this phenomenon is 
the point mutation of the gene TP53 [4, 5]. 
Mutations in TP53 head for creating a protein with a de-
creased activity, or a native protein which is not capable of reg-
ulating the cell cycle and effectively fulfilling its function [6, 7]. 
The mutated p35 protein supports the survival and pro-
liferation of neoplastic cells, inhibits their apoptosis, and 
promotes resistance to chemotherapy. The altered form 
of the protein has a longer half-life in the organism, which 
enables its determination in the extracellular fluid, including 
blood serum [8].
The studies concerning ovarian neoplasms conducted 
so far also indicate disturbances in humoral immune re-
sponse manifesting itself in production of autoantibodies 
anti-p53 [9, 10]. Detection of anti-p53 autoantibodies in 
biological fluids are the result of the secondary humoral 
response directed against the mutated protein p53. They 
belong to antibodies of IgG class and may be detected 
even after several years from diagnosing a neoplastic 
change [11, 12]. 
520
Ginekologia Polska 2020, vol. 91, no. 9
www. journals.viamedica.pl/ginekologia_polska
Due to the fact that the systemic changes accompanying 
ovarian neoplasms and occurring with soluble apoptosis 
mediators are still not fully known, their fuller evaluation 
requires further studying. Taking into the account that these 
changes may perform a crucial function in the pathogenesis 
of ovarian cancers and that the concentration of the immune 
system soluble mediators in body fluids may be applied in 
clinical practice, the primary objective of the paper was to 
assess the concentration of p53 protein and anti-p53 au-
toantibodies in the serum of women with ovarian tumours. 
MATERIAL AND METHODS
This study had 74 women aged 23 to 70 years (mean age: 
37.5 ± 9.42 years), who were diagnosed with ovarian cancer, 
qualified for the study. In this group, 20 women had Cystad-
enoma serosum and 54 women had Cystadenocarcinoma 
papillare serosum at IIIc stage according to the FIGO classi-
fication and, within the group, 10 patients were diagnosed 
with G1, 14 were diagnosed with G2, and the remaining 
30 were diagnosed with G3 staging. Clinical diagnosis of 
the tumour was confirmed by histopathological examina-
tion. Any other reproductive system disease was not found 
in the examined women. The patients were hospitalized in 
the Clinical Ward of Obstetrics and Gynecology, Women’s 
Health Chair, Medical University of Silesia in Ruda Śląska. The 
control group included 34 healthy women aged between 
27–60 (mean age: 45.34 ± 19.25 years). No pathological 
changes in these women’s reproductive organs occurred. 
The research material in all  the women was the blood se-
rum. The blood was taken from women after making clinical 
diagnosis, before surgery. In the morning the blood was 
taken from the cubital vein, to a clot tube, in order to obtain 
the serum and 30 minutes after taking the blood, it was 
centrifuged at 1500 × g for 15 minutes. Until testing was 
performed, the serum was stored at –80˚ C. In the control 
group, the blood was taken while the women came for the 
check-up and the same procedure was used. Enzyme-linked 
immunosorbent assay (ELISA) was used to determine the 
concentration of the studied parameters: p53 Kit Elisa 
Gen-Probe, Diaclone and anti-p53 autoantibodies ELISA, 
Steinbeis-Transferzentrum, Angewandte Biologische Che-
mie. Test sensitivity was the following: 1.5 U/mL (for p53) 
and 0.07 U/mL (for anti-p53 autoantibodies). All the women, 
who participated in the study, consented to conducting the 
research. The approval of the Ethics Committee of the Medi-
cal University of Silesia in Katowice was obtained.
Using the computer program Statistica for Windows 
10.0 and Microsoft Excel, the results were statistically ana-
lyzed.  The Shapiro-Wilk test was used in order to verify the 
distribution of the obtained results. After verification that 
the received results corresponded to the normal distribu-
tion, the arithmetic mean (x) and standard deviation (SD) 
were calculated for each parameter. The mean values of the 
studied parameters in the studied group and the control 
group were compared by means of the Student’s t-test, while 
for nonparametric results:  Mann-Whitney’s test was used. 
Correlations were tested by Spearman’s rank correlation 
test and presented as correlation coefficient (r). P < 0.05 was 
considered statistically significant.
RESULTS
In the serum of healthy women belonging to the con-
trol group and women with ovarian serous cystadenoma, 
the concentration of the p53 was below the test sensitivity 
threshold which amounted to 1.5 U/mL. In the group of 
women with ovarian cancer, due to the fact that the ob-
tained values did not correspond with the normal distribu-
tion, the results are presented as a median and an upper 
and lower interquartile range (Q1 and Q3) which equalled 
22.14 U/mL and 47.71 U/mL, respectively, while the me-
dian value was equal to 35.89 U/mL. The conducted analysis 
of the test results revealed statistical significance between 
the concentration of the studied parameter depending on 
the degree of differentiation G1 and G3 (p < 0.001). However, 
no significant differences between the concentration of 
p53 protein in the serum of women with moderately differ-
entiated (G2) and poorly differentiated (G3) ovarian cancer 
were shown. The obtained results are shown in Figure 1. 
There was no correlation between CA125 concentration in 
the serum of women with ovarian cancer and the concentra-
tion of p53 protein in their serum.
Further analysis included the assessment of anti-p53 au-
toantibodies concentration in the studied women. In the 
serum of healthy women and women with ovarian serous 
cystadenoma, anti-p53 autoantibodies were not detected. 
Whereas in the group of women with ovarian cancer con-
centration of the parameter did not correspond with the 
Figure 1. Concentrations of p53 protein in serum of women  
depending on the degree of differentiation G1, G2 and G3
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normal distribution and therefore the results are presented 
as a median and an upper and lower interquartile range 
(Q1 and Q3), amounted to 80.30 U/mL and 170.10 U/mL 
respectively, while the median value equalled 140.92 U/mL. 
The conducted analysis of the study results revealed a sig-
nificance between the concentration of the studied param-
eter depending on the degree of differentiation G1 and 
G2 (p < 0.05) and G2 and G3 (p < 0.01). The obtained results 
are shown in Figure 2. There was no correlation between 
the concentration of CA125 in the serum of women with 
an ovarian neoplasm and anti-p53 autoantibodies concen-
tration in their serum.
Subsequently, the ratio p53/anti-p53 autoantibodies 
was determined. A statistically significant difference was 
shown for the value of this coefficient only between G1 and 
G2 (p < 0.05) in Figure 3. 
Moreover, since in the serum of women with ovar-
ian cancer, the concentration anti-p53 autoantibodies was 
three times higher than the concentration of protein p53, 
the percentage contents of protein p53 and autoantibod-
ies p53 in the total immune complex was determined. The 
analysis revealed a statistically significant increase of the 
percentage contents of p53 protein in the total immune 
complexes in the serum between G1 and G2, was illustrated 
in Figure 4. 
DISCUSSION
Studies have so far indicated that some neoplastic cells 
may reveal sensitivity to factors inducing the intrinsic path-
way of apoptosis and therefore, it is justifiable to study the 
markers of this process. It is thanks to its apoptosis conduct 
that the neoplastic fully transformed cells are eliminated. 
The imbalance between the number of proliferating cells 
and those undergoing apoptosis may be caused by the 
presence of the p53 protein. It influences the decrease of 
ability to activate the programmed death of the cell which is 
irreversibly damaged. Its presence may also lead to initiation 
of the neoplastic process. The altered form of the protein 
has a longer half-life in the organism which enables its 
determination [13, 14]. 
The previous studies concerned mostly the assessment 
of protein p53 expression in women with ovarian cancer 
using the immunohistochemical method [15], whereas in 
this study we tried to assessment of the concentration of 
this parameter in the serum of women with ovarian cancer.
In our studies, the concentration of protein p53 in the 
serum of both women with ovarian cancer and from the 
control group was assessed. The analysis included 74 female 
patients with a diagnosed serous ovarian cancer at the 
IIIC stage according to FIGO classification and with ovar-
ian serous cystadenoma. In the serum of healthy women 
constituting the control group and women with serous 
Figure 2. Concentrations of anti-p53 autoantibodies in serum of 
women  depending on the degree of differentiation G1, G2 and G3
Figure 3. p53/anti-p53 autoantibodies ratio in serum of women  
depending on the degree of differentiation G1, G2 and G3 
Figure 4. Percentage contents of p53 protein and anti-p53 
autoantibodies in serum of women depending on the degree of 
differentiation G1, G2 and G3
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cystadenoma, the concentration of p53 protein was below 
the sensitivity threshold. However, a significantly increased 
concentration of protein p53 in the serum of women with 
ovarian cancer when compared to its concentration as-
sessed in the control group was indicated. The obtained 
increased concentration of protein p53 points out to im-
pairment of the apoptotic process on the intrinsic pathway. 
Interesting was the analysis of the concentration of the 
studied parameter conducted according to the degree of 
tumour differentiation. The indicated statistical significance 
between G1 and G3 proves that the impaired apoptosis with 
protein p53 is associated with the degree of histological 
differentiation of ovarian cancer.  
Very little data are currently available on the prevalence 
of anti-p53 antibodies in patients with epithelial ovarian can-
cer [16]. Murphy et al. [17] used ELISA to detect anti-p53 anti-
body in sera in normal heath individuals and ovarian cancer 
patients, however, the distribution of anti-p53 antibody 
in the two groups showed no significant difference. Ad-
ditionally, Høgdall et al. [18] found that the frequency of 
anti-p53 antibodies in ovarian cancer patients increased 
somewhat with increasing clinical stage of disease, but the 
differences did not reach statistical significance. In contrast, 
other studies showed opposite results [19–21]. Anti-p53 an-
tibodies are often detected in serum from patients with 
advanced ovarian carcinoma [22]. Additionally, the preop-
erative serum anti-p53 antibody status had no prognostic 
relevance for progression-free survival and survival [23]. 
However, the generation of a humoral immune response 
against p53 protein in the close tumour environment, as 
demonstrated by the occurrence of anti-p53 autoantibod-
ies in the ascitic fluid of ovarian carcinoma patients, is as-
sociated with poor disease-free survival [24]. Many research-
ers have been interested in the use of autoantibodies as 
serological markers for cancer diagnosis, because of the 
absence of these autoantibodies in normal individuals and 
in non-cancer conditions. With the successive addition to 
study panel, except p53, another autoantigen tumour as-
sociate to (surviving, p16, cyclin B1, cyclin D1, cyclin A and 
cyclin E), there was a stepwise increase in sensitivity of up 
to 62.5%, and in specificity of 90.2% [19]. 
Currently, there are many studies conducted aiming at 
determination of a possible application of anti-p53 autoan-
tibodies in the diagnostics of ovarian cancer. Arjomandi 
et al. [25] presented an innovative algorithm which could 
increase the specificity and sensitivity of potential tests for 
early detection of ovarian cancer. For detection, the au-
thors used the protein p53 complex with selected antigenic 
epitopes. Based on the conducted analyses, they did not 
demonstrate the determination of the studied autoantibod-
ies in the screening diagnostics of ovarian cancer. Moreover, 
according to the authors, assessing the concentration of 
anti-p53 autoantibodies with CA125 does not constitute 
a sufficiently sensitive and specific screening test for detec-
tion of early lesions in female patients with ovarian cancer. 
Anderson et al. [20] observed a significantly increased 
concentration of autoantibodies in the serum of over 42% 
of women with serous ovarian cancer, whereas in the case 
of different histological types of cancer as well as benign 
tumours, the concentration of antibodies was considerably 
decreased. In the opinion of researchers, the application of 
anti-p53 autoantibodies as markers for early detection of 
ovarian cancer is limited due to a low sensitivity at an early 
stage of disease and non-specific reactions in the case of 
neoplasms demonstrating an increased expression of ab-
normal protein p53. 
The assessment of autoantibodies p53 application in 
monitoring the efficacy of the basic treatment therapy of 
ovarian cancer was also made by Häfner et al. [26]. The au-
thors demonstrated that antibodies p53 could constitute 
a more sensitive marker than antigen CA 125 in detecting 
minimal residual disease remaining after the surgical proce-
dure or chemotherapy. The concentration of antigen CA125, 
released by neoplastic cells, is associated with the mass of 
ovarian tumours, while the induction of antibodies p53 takes 
place in response to the occurrence of single neoplastic 
cells. According to the authors, assessing p53 antibodies 
could become useful in monitoring the maintenance and 
consolidation therapy. 
Similar studies were performed out by Dobrzycka et al. [27], 
who found antibodies p53 in 33,3% of female patients un-
dergoing aggressive treatment of ovarian cancer. A sig-
nificantly increased concentration of these antibodies was 
found in the serum of patients with serous ovarian cancer 
with III and IV clinical stage of tumour. Moreover, as a part 
of the conducted analysis in female patients with serous 
cancer anti-p53 autoantibodies positive, they assessed the 
values for the chance of one-year and five-year survival 
with a diagnosed cancer which amounted to 86.4% and 
72.7% respectively. The median of the overall survival time 
for women anti-p53 autoantibodies positive was equal to 
11 months, while for patients anti-p53 autoantibodies nega-
tive, it amounted to 57 months. In the case of women with 
mucinous cancer they did not demonstrate the correlation 
between the presence of the determined antibodies in the 
serum, and the overall survival time [27].
Our date did not demonstrate the presence of antibod-
ies p53 in the serum of healthy women and women with 
serous cystadenoma. However, there was found a signifi-
cantly increased concentration of anti-p53 autoantibodies 
complex in the serum of women with ovarian cancer. 
Interestingly, the determined coefficient p53/an-
ti-p53 autoantibodies which was almost 3-times higher 
in women with ovarian cancer than in the control group, 
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may indicate impairments in the internalization of the im-
mune complex occurrence in the system which in turn un-
doubtedly favours the induction of the immune tolerance 
in response to the growing tumour. On the other hand, 
the conducted assessment of the percentage contents of 
p53 protein and anti-p53 autoantibodies in the immune 
complex proves that patients with ovarian cancer are ac-
companied by the impairment of immunoprecipitated 
p53 protein — anti-p53 autoantibodies occurrence, while 
the excess of free antibodies in the serum may have an in-
fluence on a weaker immune reactivity by interfering with 
some soluble mediators of the immune system. In contrast, 
the increased levels of p53-AAbs in the serum of women 
with ovarian cancer indicate an increased effect of second-
ary humoral response against the mutated p53 protein, 
and they are also associated with the degree of histological 
differentiation of the tumour, and their determination may 
be used in laboratory diagnostics, which requires, however, 
further research.
CONCLUSIONS
The results of the conducted studies allow to draw the 
following conclusions:
1. The regulation of the immune response towards sup-
pression and the creation of an environment conducive 
to the proliferation of cancer cells may involve disorders 
associated with the p53 protein/anti-p53 autoantibod-
ies system.
2. The occurring systemic changes in the immune sys-
tem with soluble mediators play an important role in 
the pathogenesis of ovarian cancer. Intensification of 
apoptosis and humoral immune response impairment 
in women with ovarian cancer confirms a considerable 
involvement of p53 protein and anti-p53 autoantibodies 
in the pathogenesis of serous ovarian cancer. 
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